Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002052113-25-002222
Filing Date
2025-07-15
Accepted
2025-07-15 17:12:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5646
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2924
3 EXHIBIT 99: ITEM 7 Item_7.txt EX-99 558
  Complete submission text file 0002052113-25-002222.txt   10933
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Subject) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89108 | Film No.: 251125553
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock Portfolio Management LLC (Filed by) CIK: 0002052113 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G